PMID- 37406458
OWN - NLM
STAT- MEDLINE
DCOM- 20240209
LR  - 20240222
IS  - 1538-7151 (Electronic)
IS  - 0277-1691 (Linking)
VI  - 43
IP  - 2
DP  - 2024 Mar 1
TI  - HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian 
      Mucinous Tumors.
PG  - 134-139
LID - 10.1097/PGP.0000000000000966 [doi]
AB  - Primary mucinous ovarian carcinoma (MOC) is a rare ovarian epithelial cancer, 
      which is often refractory to chemotherapy. HER2-targeting therapy is being 
      increasingly considered in gynecologic malignancies. Although there have been 
      limited studies examining the HER2 status of such tumors, the criteria for HER2 
      expression scoring have not been standardized for MOC as it has for other sites. 
      This study aimed to survey immunohistochemical HER2 expression patterns in MOC 
      and its precursor, mucinous borderline tumor in correlation with fluorescence in 
      situ hybridization (FISH). Immunohistochemistry (IHC) for HER2 was performed on 
      12 cases of MOC and 15 mucinous borderline tumors, including 7 with 
      intraepithelial carcinoma. HER2 expression was quantified using the 
      gastric/gastroesophageal carcinoma protocol. Cases were considered 3+ if the 
      tumor cells displayed strong complete or basolateral/lateral membranous staining 
      in >/=10% of tumor cells. Cases (2+) had weak to moderate staining in >/=10% of tumor 
      cells. Cases (1+) had faint staining in >/=10% of tumor cells. Cases considered 0 
      had no staining or faint staining in <10% of tumor cells. HER2 expression was 
      also quantified with the endometrial serous carcinoma protocol, which uses a 30% 
      tumor cell positivity cutoff. FISH for HER2 was performed on all 3+ and 2+ and a 
      subset of 1+ cases. Of the MOC cases, 25% were 3+ and 1 mucinous borderline tumor 
      with intraepithelial carcinoma had 3+ staining. All 3+ IHC MOC cases had >30% 
      basolateral membranous staining. HER2 amplification was confirmed by FISH on all 
      3+ IHC cases and in one 2+ IHC case of MOC. Up to 25% of mucinous ovarian tumors 
      showed HER2 IHC overexpression with an excellent correlation between IHC and FISH 
      using the HER2 scoring protocol for either gastric/gastroesophageal carcinoma or 
      uterine serous carcinoma.
CI  - Copyright (c) 2023 by the International Society of Gynecological Pathologists.
FAU - Smithgall, Marie C
AU  - Smithgall MC
AUID- ORCID: 0000-0001-6706-0700
FAU - Yemelyanova, Anna
AU  - Yemelyanova A
FAU - Mathew, Susan
AU  - Mathew S
FAU - Gogineni, Swarna
AU  - Gogineni S
FAU - He, Bing
AU  - He B
FAU - Zhang, Taotao
AU  - Zhang T
FAU - Robinson, Brian D
AU  - Robinson BD
FAU - Tu, Jiangling J
AU  - Tu JJ
LA  - eng
PT  - Journal Article
DEP - 20230630
PL  - United States
TA  - Int J Gynecol Pathol
JT  - International journal of gynecological pathology : official journal of the 
      International Society of Gynecological Pathologists
JID - 8214845
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
SB  - IM
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - DNA Copy Number Variations
MH  - Gene Amplification
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - *Ovarian Neoplasms/genetics/pathology
MH  - Carcinoma, Ovarian Epithelial
MH  - *Neoplasms, Cystic, Mucinous, and Serous
MH  - *Adenocarcinoma, Mucinous/genetics
MH  - *Endometrial Neoplasms
MH  - *Cystadenocarcinoma, Serous
MH  - *Carcinoma in Situ
MH  - Biomarkers, Tumor/genetics
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/06 01:08
MHDA- 2024/02/09 06:42
CRDT- 2023/07/05 18:04
PHST- 2024/02/09 06:42 [medline]
PHST- 2023/07/06 01:08 [pubmed]
PHST- 2023/07/05 18:04 [entrez]
AID - 00004347-202403000-00004 [pii]
AID - 10.1097/PGP.0000000000000966 [doi]
PST - ppublish
SO  - Int J Gynecol Pathol. 2024 Mar 1;43(2):134-139. doi: 
      10.1097/PGP.0000000000000966. Epub 2023 Jun 30.